BR112022010798A2 - Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo - Google Patents

Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo

Info

Publication number
BR112022010798A2
BR112022010798A2 BR112022010798A BR112022010798A BR112022010798A2 BR 112022010798 A2 BR112022010798 A2 BR 112022010798A2 BR 112022010798 A BR112022010798 A BR 112022010798A BR 112022010798 A BR112022010798 A BR 112022010798A BR 112022010798 A2 BR112022010798 A2 BR 112022010798A2
Authority
BR
Brazil
Prior art keywords
phenylisoxazolyl
naphthalene
methylene
pharmaceutical composition
ether derivative
Prior art date
Application number
BR112022010798A
Other languages
English (en)
Inventor
Yang Bailing
Kristjan Gudmundsson
Dong Liuyu
Chen James
Original Assignee
Gannex Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gannex Pharma Co Ltd filed Critical Gannex Pharma Co Ltd
Publication of BR112022010798A2 publication Critical patent/BR112022010798A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

DERIVADO DE METILENO-NAFTALENO-ÉTER DE FENILISOXAZOLILA, SEU USO E COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO. A presente invenção fornece um método para tratar ou prevenir infecção pelo vírus da hepatite B em um humano ou animal, compreendendo administrar ao humano ou animal em necessidade do mesmo uma quantidade terapeuticamente eficaz de um derivado de fenilisoxazolil metileno-naftaleno-éter tendo uma estrutura de fórmula (I); uso de um derivado de fenilisoxazolil metileno-naftaleno-éter tendo uma estrutura de fórmula (I) na preparação de uma composição farmacêutica para o vírus anti-hepatite B e uma composição farmacêutica para o vírus anti-hepatite B.
BR112022010798A 2019-12-03 2020-10-12 Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo BR112022010798A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/122595 WO2021108974A1 (en) 2019-12-03 2019-12-03 Compounds for modulating activity of fxr and uses thereof
PCT/CN2020/120370 WO2021109713A1 (en) 2019-12-03 2020-10-12 Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives

Publications (1)

Publication Number Publication Date
BR112022010798A2 true BR112022010798A2 (pt) 2022-08-23

Family

ID=76111005

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022010638A BR112022010638A2 (pt) 2019-12-03 2020-10-12 Compostos para modular a atividade de fxr e usos dos mesmos
BR112022010798A BR112022010798A2 (pt) 2019-12-03 2020-10-12 Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022010638A BR112022010638A2 (pt) 2019-12-03 2020-10-12 Compostos para modular a atividade de fxr e usos dos mesmos

Country Status (13)

Country Link
US (2) US20230165843A1 (pt)
EP (2) EP4073070A4 (pt)
JP (2) JP7430263B2 (pt)
KR (2) KR20220112278A (pt)
CN (2) CN112891348B (pt)
AU (2) AU2020395393B2 (pt)
BR (2) BR112022010638A2 (pt)
CA (2) CA3163779A1 (pt)
CO (2) CO2022008719A2 (pt)
IL (2) IL293507A (pt)
MX (2) MX2022006653A (pt)
PE (2) PE20230235A1 (pt)
WO (3) WO2021108974A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof
TW202317110A (zh) * 2021-07-06 2023-05-01 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
TW202315608A (zh) * 2021-07-06 2023-04-16 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
WO2023035181A1 (en) * 2021-09-09 2023-03-16 Gannex Pharma Co., Ltd. A pharmaceutical composition of fxr agonist and its preparation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013946A (es) 2007-07-02 2010-03-10 Glaxosmithkline Llc Agonistas del receptor de farnesoide x.
RS61540B1 (sr) * 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
EP3193869A1 (en) * 2014-08-14 2017-07-26 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Perk activator for the treatment of neurodegenerative diseases
US10080743B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080741B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2018190643A1 (en) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
US10829486B2 (en) * 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2021108974A1 (en) * 2019-12-03 2021-06-10 Gannex Pharma Co., Ltd Compounds for modulating activity of fxr and uses thereof

Also Published As

Publication number Publication date
CA3163779A1 (en) 2021-06-10
AU2020395393A1 (en) 2022-06-23
JP7430263B2 (ja) 2024-02-09
PE20230182A1 (es) 2023-02-01
CO2022008701A2 (es) 2022-07-19
MX2022006653A (es) 2022-07-05
AU2020395393B2 (en) 2023-07-06
CN112891348A (zh) 2021-06-04
WO2021108974A1 (en) 2021-06-10
US20220388997A1 (en) 2022-12-08
WO2021109713A1 (en) 2021-06-10
MX2022006742A (es) 2022-08-15
KR20220112278A (ko) 2022-08-10
AU2020397245B2 (en) 2024-02-29
PE20230235A1 (es) 2023-02-07
CN112898289B (zh) 2022-11-04
AU2020397245A1 (en) 2022-06-30
IL293507A (en) 2022-08-01
EP4073071A1 (en) 2022-10-19
JP2023505205A (ja) 2023-02-08
EP4073071A4 (en) 2023-11-01
CA3159899A1 (en) 2021-06-10
CN112898289A (zh) 2021-06-04
JP2023504690A (ja) 2023-02-06
EP4073070A1 (en) 2022-10-19
BR112022010638A2 (pt) 2022-08-16
WO2021109712A1 (en) 2021-06-10
KR20220101697A (ko) 2022-07-19
EP4073070A4 (en) 2023-10-18
CO2022008719A2 (es) 2022-07-19
CN112891348B (zh) 2022-06-28
US20230165843A1 (en) 2023-06-01
IL293497A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
BR112018075682A2 (pt) inibidores de papd5 e papd7 para tratamento de infecção pela hepatite b
CY1118059T1 (el) Συνθεσεις αντιλοιμωδων βασει λιπιδιων για αγωγη πνευμονικων λοιμωξεων
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
BRPI0509467A (pt) compostos macrocìclicos como inibidores de replicação viral
WO2005020884A3 (en) Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
MX2022011111A (es) Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
BR112021017415A2 (pt) Derivados de pirimidona de anel fundido para uso no tratamento de infecção por vhb ou de doenças induzidas por vhb
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BRPI0508079A (pt) composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022001567A2 (pt) Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias.
BR112021022889A8 (pt) Derivados heterocíclicos fundidos, seus usos, composição farmacêutica e produto compreendendo os mesmos e método para a preparação dos mesmos
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112022016131A2 (pt) Compostos para tratamento de infecção por coronavírus
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112022015771A2 (pt) Compostos tetracíclicos para tratar a infecção por hiv
BR112022019357A2 (pt) Medicamento/agente para o tratamento de coronavírus, infecções retrovirais e hepatite c
BR112022018504A2 (pt) Usos de uma composição